Beacon Biosignals is dedicated to building the future of brain health using AI-driven neurotechnology. The company tackles the challenge of neurological and psychiatric conditions, aiming to bring precision neuroscience to clinical trials and accelerate drug development for unmet medical needs, so life-changing treatments can reach patients faster.

Beacon's platform utilizes an FDA-cleared headband to collect high-fidelity sleep EEG data at home or clinical settings. Their AI models analyze over 200,000 hours of EEG data to characterize brain function. This technology enables identification of novel biomarkers, assessment of treatment effects, and patient stratification with greater accuracy and less burden than traditional methods.

The company supports clinical development teams with compliance monitoring, treatment response assessment, and clinical trial support. Their biomarkers detect dose-dependent drug effects, characterize patient populations, expand labeling language, and allow early tracking of disease progression.

Beacon Biosignals supports all stages of therapeutic development from discovery to clinical practice by providing tools to extract insights from EEG data, optimize trials with objective sleep endpoints, and differentiate treatments through real-world evidence.